Preliminary results from digestive adaptation
a new surgical proposal for treating obesity, based on physiology and evolution
Keywords:
Morbid obesit, Surgery, Ghrelin, Glucagon-like peptide 1, Peptide YYAbstract
CONTEXT AND OBJECTIVE: Most bariatric surgical techniques include essentially non-physi- ological features like narrowing anastomoses or bands, or digestive segment exclusion, especially the duodenum. This potentially causes symptoms or complications. The aim here was to report on the preliminary results from a new surgical technique for treating morbid obesity that takes a physiological and evolutionary approach. DESIGN AND SETTING: Case series description, in Hospital Israelita Albert Einstein and Hospital da Polícia Militar, São Paulo, and Hospital Vicentino, Ponta Grossa, Paraná. METHODS: The technique included vertical (sleeve) gastrectomy, omentectomy and enterec- tomy that retained three meters of small bowel (initial jejunum and most of the ileum), i.e. the lower limit for normal adults. The operations on 100 patients are described. RESULTS: The mean follow-up was nine months (range: one to 29 months). The mean reductions in body mass index were 4.3, 6.1, 8.1, 10.1 and 10.7 kg/m2, respectively at 1, 2, 4, 6 and 12 months. All patients reported early satiety. There was major improvement in comorbidities, especially diabetes. Operative complications occurred in 7% of patients, all of them resolved without sequelae. There was no mortality. CONCLUSIONS: This procedure creates a proportionally reduced gastrointestinal tract, leaving its basic functions unharmed and pro- ducing adaptation of the gastric chamber size to hypercaloric diet. It removes the sources of ghrelin, plasminogen activator inhibitor-1 (PAI-1) and resistin production and leads more nutrients to the distal bowel, with desirable metabolic consequences. Patients do not need nutritional support or drug medication. The procedure is straightforward and safe.
Downloads
References
Byrne TK. Complications of surgery for obesity. Surg Clin North Am. 2001;81(5):1181-93, vii-viii.
Favretti F, Cadiere GB, Segato G, et al. Laparoscopic adjustable silicone gastric banding (Lap-Band): how to avoid complica- tions. Obes Surg. 1997;7(4):352-8.
Castillo J, Fábrega E, Escalante CF, et al. Liver transplanta- tion in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity. Obes Surg. 2001;11(5):640-2.
Cotler SJ, Vitello JM, Guzman G, Testa G, Benedetti E, Layden TJ.. Hepatic decompensation after gastric bypass surgery for severe obesity. Dig Dis Sci. 2004;49(10):1563-68.
Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon- like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300-4.
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301-7.
Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hy- perglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care. 1996;19(6):580-6.
Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon- like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci. 1995;40(5):1074-82.
Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon- like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 Pt 1):E981-8.
Schirra J, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut. 2002;50(3):341-8.
Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 2002;18(1-2):7-14.
Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol. 2002;440(2-3):235-54.
Penalva A, Baldelli R, Camina JP, et al. Physiology and possible pathology of growth hormone secretagogues. J Pediatr Endocri- nol Metab. 2001;14(Suppl 5):1207-12; discussion 1261-2.
Pinkney J, Williams G. Ghrelin gets hungry. Lancet. 2002;359(9315):1360-1.
Lustig RH. The neuroendocrinology of obesity. Endocrinol Metab Clin North Am. 2001;30(3):765-85.
Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623-30.
Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med. 2000;32(Suppl 1):78-84.
van Hinsbergh VW, Kooistra T, Scheffer MA, Hajo van Bockel J, van Muijen GN. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. Blood. 1990;75(7):1490-7.
Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resis- tance and risk of cardiovascular events. Thromb Haemost. 1997;78(1):656-60.
Carmichael AR, Tate G, King RF, Sue-Ling HM, Johnston D. Effects of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator inhibitor type 1, tissue plasmino- gen activator, fibrinogen and insulin. Pathophysiol Haemost Thromb. 2002;32(1):40-3.
Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord. 2002;26(2):193-9.
McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab. 2002;87(5):2407.
McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet. 2002;359(9300):46-7.
Bergman RN, Van Citters GW, Mittelman SD, et al. Central role of the adipocyte in the metabolic syndrome. J Investig Med. 2001;49(1):119-26.
Batterham RL, Bloom SR. The gut hormone peptide YY regu- lates appetite. Ann N Y Acad Sci. 2003;994:162-8.
Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88(10):4696-701.
van den Hoek AM, Heijboer AC, Corssmit EP, et al. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high- fat diet. Diabetes. 2004;53(8):1949-52.
Stevens CE, Hume ID. Comparative Physiology of the Vertebrate Digestive System. 2nd ed. Cambridge: Cambridge University Press; 1995.
Milton K. A hypothesis to explain the role of meat-eat- ing in human evolution. Evolutionary Anthropology. 1999;8(1):11-21.
Milton K. Primate diets and gut morphology: implications for hominid evolution. In: Harris M, Ross EB, editors. Food and evolution: toward a theory of human food habits.. Philadelphia: Temple University Press; 1987. p. 93-115.
Aiello LC, Wheeler P. The expensive tissue hypothesis: The brain and the digestive system in human and primate evolution. Cur Anthropol. 1995;36:199-221.
Leonard WR, Robertson ML. Evolutionary perspectives on human nutrition: the influence of brain and body size on diet and metabolism. Am J Hum Biol. 1994;6:77-88.
Lugari R, Dei Cas A, Ugolotti D, et al. Evidence for early impair- ment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res. 2002;34(3):150-4.
Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut. 1996;38(6):916-9.
Hounnou G, Destrieux C, Desme J, Bertrand P, Velut S. Ana- tomical study of the length of the human intestine. Surg Radiol Anat. 2002;24(5):290-4.
Santoro S, Velhote MCP, Mechenas ASG, Malzoni CE, Strass- mann V. Gastro-omentectomia Laparoscópica Adaptativa: Novo Procedimento para Tratamento e Prevenção do Avanço da Obesi- dade - Bases Fisiológicas e Evolucionárias. [Laparoscopic adaptive gastro-omentectomy as an early procedure to treat and prevent the progress of obesity - evolutionary and physiological support]. Revista Brasileira de Videocirurgia. 2003;1(3):96-102.
Santoro S. Relações entre o comprimento do intestino e a obesidade. Hipótese: a síndrome do intestino longo. Einstein. 2003;1:44-46. Available from: http://www.einstein.br/biblioteca/pdf/On%20line%2030.pdf. Accessed in 2006 (Jul 5).
Santoro S, Velhote MCP, Malzoni CE, Mechenas ASG, Strassmann V, Scheinberg. Adaptação digestive: uma nova proposta cirúrgica para tartar a obesidade com base em fisiolo- gia e evolução. [Digestive adaptation: a new surgical proposal to treat obesity based in physiology and evolution]. Einstein. 2003;1(2):99-104. Available from: http://www.einstein.br/biblioteca/artigos/adaptação%20digestiva%20traduzido.pdf. Accessed in 2006 (Jul 5).
Baltasar A, Bou R, Bengochea M, et al. Duodenal switch: an effective therapy for morbid obesity--intermediate results. Obes Surg. 2001;11(1):54-8.
Adkins Jr RB, Davies J. Gross and microscopic anatomy of the stomach and small intestine. In: Scott Jr HW, Sawyers JL, editors. Surgery of the stomach, duodenum and small bowel. Boston: Blackwell Scientific Publications; 1987. p. 45-60
Gardner E. O abdomen. Estudo regional do corpo humano. In: Gardner E, Gray DS, Rahylly R, editors. Anatomia. Rio de Janeiro: Guanabara Koogan; 1967. p. 407-84.
Santoro S, Velhote MCP, Malzoni CE, Mechenas ASG, Damiani D, Maksoud JG. Adaptação digestive com reserve intestinal: nova proposta cirúrgica para obesidade mórbida. [Digestive adaptation with intestinal reserve: a new surgical proposal for morbid obesity]. Revista Brasileira de Videocirurgia. 2004;2(3):130-8.
